Journal article
Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma
Abstract
BACKGROUND AND METHODS: In 1981 the Clinical Trials Group of the National Cancer Institute of Canada completed a pilot study in patients with advanced-stage non-Hodgkin's lymphoma with aggressive tumor histology. That study demonstrated the potential efficacy of escalating the dose of doxorubicin used in a regimen of bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP). In the present study, we compared standard BACOP …
Authors
Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell V; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
Journal
New England Journal of Medicine, Vol. 329, No. 24, pp. 1770–1776
Publisher
Massachusetts Medical Society
Publication Date
December 9, 1993
DOI
10.1056/nejm199312093292404
ISSN
0028-4793